Home Companies Catalysts Deep Dives
Bridion sugammadex APPROVED
Drug Profile
ModalitySmall molecule
RouteIV
Therapy AreaOther
Launch2015-12-15
US LOE2026-12-01
Peak Sales Est$2000M
Formulations[{"id":"bridion-iv","route":"IV","setting":"HOSPITAL","frequency":"Single dose","is_primary":true}]
Companies
MRK (ORIGINATOR)100%
Mechanism: Cyclodextrin encapsulator
Expert: Modified gamma-cyclodextrin selectively encapsulating rocuronium/vecuronium
Everyday: Traps and removes muscle relaxant drugs
Targets: []
Revenue History
PeriodRevenue ($M)
2023$1,680M
2024$1,760M
2025$1,850M
Q1 2025$441M
Q2 2025$460M
Q3 2025$475M
Q4 2025$474M
Programs (1)
IndicationStageKey StudyRegional Status
Neuromuscular Blockade ReversalAPPROVEDP05764[{"stage":"APPROVED","region":"US","approval_date":"2015-12-15"}]
Notes
Neuromuscular blockade reversal agent. Stable hospital product.
Data from Supabase · Updated 2026-03-24